Connor Iapoce

Michael Freeman joins Veeral Sheth, MD to discuss the history of Ocutrx, its OcuLenz and OR-Bot products, and what he envisions in the next decade at the company.

Improvements in multiple sign efficacy endpoints were observed in the full study population, with more pronounced effects in the TNFR1 genetic biomarker population.

A higher serum ferritin threshold could lead to better diagnosis and treatment of more women with iron deficiency.

Knowledge, attitudes, and practices remain relevant for disease management among patients with anemia.

High-impact chronic pain is a severely affected subgroup in SCD and is associated with greater pain burden and worse health outcomes.

A lower FACIT-Fatigue score, indicating higher fatigue was independently associated with female sex, a high BMI, a high stress level, and poor sleep quality.

Daprodustat 25-30 mg was linked to the most significant rise in serum hemoglobin and reduced serum ferritin levels.

This month-in-review features an exclusive interview with Srinivas R. Sadda, MD, and promising data from studies on geographic atrophy, diabetic macular ischemia, diabetic retinopathy, and AMD.

Topline results from the randomized, placebo-controlled Phase 3 clinical trial demonstrated a statistically significant 87% reduction in IgG4-RD flares.

Our May 2024 month-in-review for hematology focuses on important FDA updates, new anemia data from ERA 2024, and the latest imaging modalities.

Cindy X. Cai, MD, describes how both place and individual-level factors are associated with lapses in diabetic retinopathy care.

Topline data from the pivotal Phase 3 trial show plozasiran met the primary endpoint of triglyceride-lowering in patients with the ultrarare genetic disease.

A quality improvement initiative exhibited a sustained increase in transcranial Doppler screening rates over an 8-year intervention period.

Diagnostic tests for anemia etiology are infrequently ordered, leading to a significant majority of patients with CKD receiving inadequate treatment.

Results from a Phase I trial showed significant LDL-C reduction with AZD0780 plus statin therapy in treatment-naive patients with hypercholesterolemia.

At ARVO 2024, Dimitra Skondra, MD, describes the association between metformin use and decreased new-onset ICD coding of GA.

Blocking IL-33 production with statins may be an effective preventive strategy to suppress chronic inflammation and the development of certain cancers.

Iron administration did not increase the mortality risk of hemodialysis patients with cancer, but the safety of increasing ESA doses was not confirmed.

Alirocumab added to high-intensity statin therapy did not further improve endothelial function in patients with acute myocardial infarction.

Deepak Sambhara, MD, describes the influence of baseline central retinal thickness on visual outcomes in a post-hoc analysis of the PHOTON study.

Phase 2b study results show that investigational plozasiran significantly reduced triglyceride-rich lipoproteins in patients with mixed hyperlipidemia.

ORION-8 demonstrates the consistent long-term efficacy and tolerability of twice-yearly inclisiran over a mean cumulative exposure of 3.7 years.

Aflibercept 8 mg exhibited clinically meaningful visual, anatomic improvements at Week 48 in patients with DME regardless of baseline visual acuity.

Pre-dose IOP outcomes in eyes with DME receiving intravitreal aflibercept 8 mg or 2 mg were comparable and remained stable through Week 48.

Announced on May 22, 2024, the Roche Diagnostics Tina-quant® Lp(a) assay measures lipoprotein (a) in a person’s bloodstream to evaluate cardiovascular risk.

A cable-transmission magnetically controlled capsule endoscopy showed comparability to conventional methods in upper GI tract examinations and lesion detection.

Data from PREEMPT CRC reveal the blood-based screening test demonstrated a 79.2% sensitivity for detecting colorectal cancer.

Both doses of guselkumab exhibited statistical superiority on all prespecified pooled endoscopic endpoints versus ustekinumab in Crohn's disease.

The phase 3 QUASAR Maintenance study met its primary endpoint of clinical remission and demonstrated statistically significant endoscopic remission rates in UC treatment.

Sehgal explains the safety and efficacy of GLP-1RAs in patients with IBD as well as the impact on inflammatory biomarkers.